Gregory J. Flesher Appointed President and Chief Executive Officer SAN DIEGO, December 9, 2020 – Reneo Pharmaceuticals, Inc. today announced it raised $95 million in a Series B financing co-led by Novo Ventures and Abingworth and supported by existing investors New Enterprise Associates, RiverVest Venture Partners, Pappas Capital, and Lundbeckfonden Ventures, as well as… Continue reading Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and Abingworth
A global clinical trial is slated to begin for early next year to evaluate REN001 for the treatment of primary mitochondrial myopathies (PMM), including MELAS syndrome For LCHAD deficiency and other fatty acid oxidation disorders (FAOD), a Phase 1b clinical trial is currently recruiting and expanding globally and an international observational study is planned… Continue reading Reneo Receives Orphan Drug Designations from the EMA for REN001 for the Treatment of LCHAD Deficiency and MELAS Syndrome and Moves Forward with Clinical Trials
A small biotech company is aiming to recharge tired cells, giving mitochondrial disease patients new hope of a disease-specific treatment. “We focus on patients, going after disease with high unmet needs, like primary mitochondrial myopathies,” Niall O’Donnell, Ph.D., President, CEO and Director of Reneo Pharmaceuticals, told BioSpace. https://www.biospace.com/article/restoring-cellular-power-outages-a-new-drug-to-treat-mitochondrial-diseases/
Recently completed clinical study is informing the design of a large, global PMM clinical trial, which is planned to begin early 2021; summary to be presented at UMDF Power Surge 2020 SAN DIEGO, June 23, 2020 – Reneo Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development… Continue reading Reneo Pharmaceuticals Completes Clinical Study in Primary Mitochondrial Myopathies and Receives FDA Orphan Drug Designation for REN001
San Diego – February 18, 2020 – Reneo Pharmaceuticals, a clinical stage pharmaceutical company, today announced that it has expanded its clinical development program for REN001, into glycogen storage disease type V (GSD V), also known as McArdle disease. The company is currently recruiting participants into a Phase 1b clinical trial in the United Kingdom… Continue reading Reneo Pharmaceuticals Initiates Clinical Trial in McArdle Disease
San Diego – September 20, 2019 – Reneo Pharmaceuticals, a clinical stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to the company’s lead drug candidate, REN001, for the treatment of fatty acid oxidation disorders (FAOD). “There is a pressing… Continue reading FDA Grants Orphan Drug Designation to Reneo Pharmaceuticals for REN001 for Treatment of Fatty Acid Oxidation Disorders
San Diego – August 30, 2019 – Reneo Pharmaceuticals, a clinical stage pharmaceutical company, today announced that Alex Dorenbaum, MD, chief medical officer, will present at the INFORM (International Network for Fatty Acid Oxidation Research and Management) annual conference in Amsterdam, Netherlands, September 2, 2019. The conference focuses on the most recent advances in diagnosis… Continue reading Reneo Pharmaceuticals Announces Presentations at the INFORM Conference in Amsterdam
San Diego – May 20, 2019 – Reneo Pharmaceuticals, a clinical stage pharmaceutical company, today announced that it has completed a $50 million Series A financing to develop therapies for diseases associated with deficits in cellular metabolism and energy production. The A round was led by New Enterprise Associates. Other participants in the round include… Continue reading Reneo Pharmaceuticals Raises $50 Million to Develop Therapeutics to Treat Genetic Mitochondrial Diseases
